In contrast, in monarchE trial the addition of abemaciclib to endocrine therapy for patients with ER+/HER2- high-risk early breast cancer resulted in a significant 30% reduction in the risk of developing an IDFS event (58). This evidence concerns the gene ERBB2 and breast carcinoma.